Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 11.

Journal Article

Al-Sawaf, Othman ORCID: 0000-0001-9895-0570, Gentile, Brittany ORCID: 0000-0002-6302-5593, Devine, Jacob, Zhang, Can, Sail, Kavita, Tandon, Maneesh, Fink, Anna-Maria, Kutsch, Nadine, Wendtner, Clemens-Martin, Eichhorst, Barbara, Hallek, Michael and Fischer, Kirsten (2021). Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial. Am. J. Hematol., 96 (9). S. 1112 - 1120. HOBOKEN: WILEY. ISSN 1096-8652

Al-Sawaf, Othman, Zhang, Can, Lu, Tong, Liao, Michael Z., Panchal, Anesh, Robrecht, Sandra, Ching, Travers ORCID: 0000-0002-5577-3516, Tandon, Maneesh, Fink, Anna-Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Boettcher, Sebastian, Kreuzer, Karl-Anton, Chyla, Brenda, Miles, Dale, Wendtner, Clemens-Martin, Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael and Fischer, Kirsten (2021). Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. J. Clin. Oncol., 39 (36). S. 4049 - 4062. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Al-Sawaf, Othman, Zhang, Can, Tandon, Maneesh, Sinha, Arijit, Fink, Anna Maria, Robrecht, Sandra, Tausch, Eugen, Schary, William L., Ritgen, Matthias, Wendtner, Clemens Martin, Kreuzer, Karl A., Eichhorst, Barbara, Stilgenbauer, Stephan, Hallek, Michael J. and Fischer, Kirsten (2020). Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Al-Sawaf, Othman, Zhang, Can, Tandon, Maneesh, Sinha, Arijit, Fink, Anna-Maria, Robrecht, Sandra, Samoylova, Olga, Liberati, Anna M., Pinilla-Ibarz, Javier, Opat, Stephen, Sivcheva, Liliya, Le Du, Katell, Fogliatto, Laura M., Niemann, Carsten U., Weinkove, Robert, Robinson, Sue, Kipps, Thomas J., Tausch, Eugen, Schary, William, Ritgen, Matthias, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Eichhorst, Barbara, Stilgenbauer, Stephan, Hallek, Michael and Fischer, Kirsten (2020). Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol., 21 (9). S. 1188 - 1201. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Cramer, Paula ORCID: 0000-0003-4046-9922, Furstenau, Moritz, Robrecht, Sandra, Giza, Adam, Zhang, Can, Fink, Anna-Maria, Fischer, Kirsten, Langerbeins, Petra, Al-Sawaf, Othman, Tausch, Eugen, Schneider, Christof, Schetelig, Johannes, Dreger, Peter, Bottcher, Sebastian, Kreuzer, Karl-Anton, Schilhabel, Anke, Ritgen, Matthias, Bruggemann, Monika, Kneba, Michael, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2022). Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG) a multicentre, open-label, phase 2 trial. Lancet Haematol., 9 (10). S. E745 - 11. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

Huber, Henriette, Edenhofer, Simone, von Tresckow, Julia, Robrecht, Sandra, Zhang, Can, Tausch, Eugen, Schneider, Christof, Bloehdorn, Johannes ORCID: 0000-0003-1433-9702, Fuerstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna L., Duerig, Jan, Boettcher, Sebastian, Niemann, Carsten U., Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Doehner, Hartmut, Hallek, Michael ORCID: 0000-0002-7425-4455, Eichhorst, Barbara and Stilgenbauer, Stephan (2022). Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood, 139 (9). S. 1318 - 1330. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Huber, Henriette, Tausch, Eugen, Schneider, Christof, Edenhofer, Simone, Von Tresckow, Julia, Robrecht, Sandra, Giza, Adam, Zhang, Can, Furstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna Lena, Duerig, Jan, Boettcher, Sebastian, Niemann, Carsten Utoft, Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Doehner, Hartmut, Hallek, Michael, Eichhorst, Barbara and Stilgenbauer, Stephan (2022). Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kajueter, Hiltraud, Wellmann, Ina, Khil, Laura, Jockel, Karl-Heinz, Zhang, Can, Fink, Anna-Maria, Hallek, Michael and Stang, Andreas (2021). Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany. Blood Cancer J., 11 (10). LONDON: SPRINGERNATURE. ISSN 2044-5385

Kutsch, Nadine, Bahlo, Jasmin, Robrecht, Sandra, Franklin, Jeremy, Zhang, Can, Maurer, Christian, De Silva, Nisha, Lange, Elisabeth, Weide, Rudolf, Kiehl, Michael G., Soekler, Martin, Schlag, Rudolf, Vehling-Kaiser, Ursula, Koechling, Georg, Ploeger, Christoph, Gregor, Michael, Plesner, Torben, Herling, Marco, Fischer, Kirsten, Doehner, Hartmut, Kneba, Michael, Wendtner, Clemens-Martin, Klapper, Wolfram, Kreuzer, Karl-Anton, Boettcher, Sebastian, Stilgenbauer, Stephan, Fink, Anna Maria, Hallek, Michael and Eichhorst, Barbara (2020). Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG). Hemasphere, 4 (1). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Langerbeins, Petra, Zhang, Can, Robrecht, Sandra, Cramer, Paula, Fuerstenau, Moritz, Al-Sawaf, Othman, von Tresckow, Julia, Fink, Anna-Maria, Kreuzer, Karl-Anton, Vehling-Kaiser, Ursula, Tausch, Eugen, Mueller, Lothar, Eckart, Michael Josef, Schlag, Rudolf, Freier, Werner, Gaska, Tobias, Balser, Christina, Reiser, Marcel, Stauch, Martina, Wendtner, Clemens-Martin, Fischer, Kirsten, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2021). The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia. Blood, 139 (2). S. 177 - 188. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Tausch, Eugen, Schneider, Christof, Robrecht, Sandra, Zhang, Can, Dolnik, Anna, Bloehdorn, Johannes, Bahlo, Jasmin, Al-Sawaf, Othman, Ritgen, Matthias, Fink, Anna-Maria, Eichhorst, Barbara, Kreuzer, Karl-Anton, Tandon, Maneesh, Humphrey, Kathryn, Jiang, Yanwen, Schary, William, Bullinger, Lars, Mertens, Daniel, Lura, Michele Porro, Kneba, Michael, Doehner, Hartmut, Fischer, Kirsten, Hallek, Michael and Stilgenbauer, Stephan (2020). Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood, 135 (26). S. 2402 - 2413. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

This list was generated on Thu Mar 28 09:40:51 2024 CET.